Drug Trial Radar · NCT06154278
Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B
Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Jul 25, 2024
Primary completion
Dec 1, 2026
Study completion Jul 1, 2027
Sponsor
- Lead sponsor
- University of Maryland, BaltimoreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Arbutus Biopharma Corporation
- First posted
- Dec 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn about the action of Imdusiran (AB-729) in the liver of people with chronic hepatitis B. The main questions it aims to answer are: * how well is it working in the liver * how does Imdusiran affect the hepatitis B virus Participants will receive injections of Imdusiran, one injection every 8 weeks, for a total of 4 doses. They will also undergo 2 liver biopsies: one with the first dose of Imdusiran, and the second 8 weeks after the last dose of Imdusiran.
Conditions
- Chronic Hepatitis B
Interventions
Imdusiran (AB-729)Drug
60mg subcutaneously, every 8 weeks, for a total of 4 doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intrahepatic concentration of Imdusiran (AB-729)Time frame: During intervention (with first dose of Imdusiran) and after intervention (8 weeks after last dose of Imdusiran)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Human Virology, University of Maryland School of Medicine
Baltimore, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.